Perna G, Alciati A, Riva A, Micieli W, Caldirola D (March 2016). "Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review". Current Psychiatry Reports. 18 (3): 23. doi:10.1007/s11920-016-0668-3. ISSN1535-1645. PMID26830881. S2CID24141971.
Hettema JM, Neale MC, Kendler KS (October 2001). "A review and meta-analysis of the genetic epidemiology of anxiety disorders". The American Journal of Psychiatry. 158 (10): 1568–1578. doi:10.1176/appi.ajp.158.10.1568. ISSN0002-953X. PMID11578982.
Kessler RC, DuPont RL, Berglund P, Wittchen HU (December 1999). "Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys". The American Journal of Psychiatry. 156 (12): 1915–1923. doi:10.1176/ajp.156.12.1915. ISSN0002-953X. PMID10588405. S2CID6527201.
Vahedi Z, Saiphoo A (2018). "The association between smartphone use, stress, and anxiety: A meta-analytic review". Stress & Health. 34 (3). Wiley: 347–358. doi:10.1002/smi.2805. PMID29673047.
Jiaxin Y, Xi F, Xiaoli L, Yamin L (2020). "Association of problematic smartphone use with poor sleep quality, depression, and anxiety: A systematic review and meta-analysis". Psychiatry Research. 284. Elsevier: 112686. doi:10.1016/j.psychres.2019.112686. PMID31757638. S2CID207974088.
Keles B, McCrae N, Grealish A (2019). "A systematic review: the influence of social media on depression, anxiety and psychological distress in adolescents". International Journal of Adolescence and Youth. 25 (1). Taylor & Francis: 79–93. doi:10.1080/02673843.2019.1590851.
Augner C, Vlasak T, Aichhorn W, Barth A (2023). "The association between problematic smartphone use and symptoms of anxiety and depression—a meta-analysis". Journal of Public Health. 45 (1). Oxford University Press: 193–201. doi:10.1093/pubmed/fdab350. PMID34585243.
Damodar S, Lokemoen C, Gurusamy V, Takhi M, Bishev D, Parrill A, et al. (2022). "Trending: A Systematic Review of Social Media Use's Influence on Adolescent Anxiety and Depression". Adolescent Psychiatry. 12 (1). Bentham Science Publishers: 11–22. doi:10.2174/2210676612666220225122720.
Lopes LS, Valentini JP, Monteiro TH, de Freitas Costacurta MC, Soares LO, Telfar-Barnard L, et al. (2022). "Problematic Social Media Use and Its Relationship with Depression or Anxiety: A Systematic Review". Cyberpsychology, Behavior, and Social Networking. 25 (11). Mary Ann Liebert: 691–702. doi:10.1089/cyber.2021.0300. PMID36219756.
Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, et al. (26 August 2014). "DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia-spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders". European Archives of Psychiatry and Clinical Neuroscience. 265 (2): 87–106. doi:10.1007/s00406-014-0521-9. PMID25155875. S2CID24165894.
Barić H, Đorđević V, Cerovečki I, Trkulja V (2018-03-01). "Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials". Advances in Therapy. 35 (3): 261–288. doi:10.1007/s12325-018-0680-6. ISSN1865-8652. PMID29508154. S2CID3939726.
Parsons TD, Rizzo AA (September 2008). "Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis". Journal of Behavior Therapy and Experimental Psychiatry. 39 (3): 250–261. doi:10.1016/j.jbtep.2007.07.007. PMID17720136. S2CID6688068.
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P (January 2017). "Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis%2FYIC.0000000000000147". International Clinical Psychopharmacology. 32 (1): 49–55. doi:10.1097/YIC.0000000000000147. ISSN0268-1315. PMID27643884. S2CID29623356.
Bech P, Lönn SL, Overø KF (2010). "Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder". Journal of Clinical Psychiatry. 71 (2): 121–9. doi:10.4088/JCP.08m04749blu. PMID19961809.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (October 2012). "An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder". The World Journal of Biological Psychiatry. 13 (7): 510–516. doi:10.3109/15622975.2011.624548. ISSN1814-1412. PMID22059936. S2CID35359537.
Bandelow B, Wedekind D, Leon T (2007). "Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention". Expert Review of Neurotherapeutics. 7 (7): 769–81. doi:10.1586/14737175.7.7.769. PMID17610384. S2CID6229344.
Owen RT (2007). "Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety". Drugs of Today. 43 (9): 601–10. doi:10.1358/dot.2007.43.9.1133188. PMID17940637.
Wensel TM, Powe KW, Cates ME (2012). "Pregabalin for the Treatment of Generalized Anxiety Disorder". Annals of Pharmacotherapy. 46 (3): 424–9. doi:10.1345/aph.1Q405. PMID22395254. S2CID26320851.
Boschloo L (2014). "The impact of lifestyle factors on the 2-year course of depressive and/or anxiety disorders". Journal of Affective Disorders. 159: 73–9. doi:10.1016/j.jad.2014.01.019. PMID24679393.
Kessler RC, Keller MB, Wittchen HU (1 March 2001). "The Epidemiology of Generalized Anxiety Disorder". Psychiatric Clinics of North America. 24 (1): 19–39. doi:10.1016/S0193-953X(05)70204-5. PMID11225507.
Perna G, Alciati A, Riva A, Micieli W, Caldirola D (March 2016). "Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review". Current Psychiatry Reports. 18 (3): 23. doi:10.1007/s11920-016-0668-3. ISSN1535-1645. PMID26830881. S2CID24141971.
Hettema JM, Neale MC, Kendler KS (October 2001). "A review and meta-analysis of the genetic epidemiology of anxiety disorders". The American Journal of Psychiatry. 158 (10): 1568–1578. doi:10.1176/appi.ajp.158.10.1568. ISSN0002-953X. PMID11578982.
Kessler RC, DuPont RL, Berglund P, Wittchen HU (December 1999). "Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys". The American Journal of Psychiatry. 156 (12): 1915–1923. doi:10.1176/ajp.156.12.1915. ISSN0002-953X. PMID10588405. S2CID6527201.
Vahedi Z, Saiphoo A (2018). "The association between smartphone use, stress, and anxiety: A meta-analytic review". Stress & Health. 34 (3). Wiley: 347–358. doi:10.1002/smi.2805. PMID29673047.
Jiaxin Y, Xi F, Xiaoli L, Yamin L (2020). "Association of problematic smartphone use with poor sleep quality, depression, and anxiety: A systematic review and meta-analysis". Psychiatry Research. 284. Elsevier: 112686. doi:10.1016/j.psychres.2019.112686. PMID31757638. S2CID207974088.
Augner C, Vlasak T, Aichhorn W, Barth A (2023). "The association between problematic smartphone use and symptoms of anxiety and depression—a meta-analysis". Journal of Public Health. 45 (1). Oxford University Press: 193–201. doi:10.1093/pubmed/fdab350. PMID34585243.
Lopes LS, Valentini JP, Monteiro TH, de Freitas Costacurta MC, Soares LO, Telfar-Barnard L, et al. (2022). "Problematic Social Media Use and Its Relationship with Depression or Anxiety: A Systematic Review". Cyberpsychology, Behavior, and Social Networking. 25 (11). Mary Ann Liebert: 691–702. doi:10.1089/cyber.2021.0300. PMID36219756.
Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, et al. (26 August 2014). "DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia-spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders". European Archives of Psychiatry and Clinical Neuroscience. 265 (2): 87–106. doi:10.1007/s00406-014-0521-9. PMID25155875. S2CID24165894.
Barić H, Đorđević V, Cerovečki I, Trkulja V (2018-03-01). "Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials". Advances in Therapy. 35 (3): 261–288. doi:10.1007/s12325-018-0680-6. ISSN1865-8652. PMID29508154. S2CID3939726.
Parsons TD, Rizzo AA (September 2008). "Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis". Journal of Behavior Therapy and Experimental Psychiatry. 39 (3): 250–261. doi:10.1016/j.jbtep.2007.07.007. PMID17720136. S2CID6688068.
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P (January 2017). "Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis%2FYIC.0000000000000147". International Clinical Psychopharmacology. 32 (1): 49–55. doi:10.1097/YIC.0000000000000147. ISSN0268-1315. PMID27643884. S2CID29623356.
Bech P, Lönn SL, Overø KF (2010). "Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder". Journal of Clinical Psychiatry. 71 (2): 121–9. doi:10.4088/JCP.08m04749blu. PMID19961809.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (October 2012). "An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder". The World Journal of Biological Psychiatry. 13 (7): 510–516. doi:10.3109/15622975.2011.624548. ISSN1814-1412. PMID22059936. S2CID35359537.
Bandelow B, Wedekind D, Leon T (2007). "Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention". Expert Review of Neurotherapeutics. 7 (7): 769–81. doi:10.1586/14737175.7.7.769. PMID17610384. S2CID6229344.
Owen RT (2007). "Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety". Drugs of Today. 43 (9): 601–10. doi:10.1358/dot.2007.43.9.1133188. PMID17940637.
Wensel TM, Powe KW, Cates ME (2012). "Pregabalin for the Treatment of Generalized Anxiety Disorder". Annals of Pharmacotherapy. 46 (3): 424–9. doi:10.1345/aph.1Q405. PMID22395254. S2CID26320851.
Boschloo L (2014). "The impact of lifestyle factors on the 2-year course of depressive and/or anxiety disorders". Journal of Affective Disorders. 159: 73–9. doi:10.1016/j.jad.2014.01.019. PMID24679393.
Kessler RC, Keller MB, Wittchen HU (1 March 2001). "The Epidemiology of Generalized Anxiety Disorder". Psychiatric Clinics of North America. 24 (1): 19–39. doi:10.1016/S0193-953X(05)70204-5. PMID11225507.
Perna G, Alciati A, Riva A, Micieli W, Caldirola D (March 2016). "Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review". Current Psychiatry Reports. 18 (3): 23. doi:10.1007/s11920-016-0668-3. ISSN1535-1645. PMID26830881. S2CID24141971.
Kessler RC, DuPont RL, Berglund P, Wittchen HU (December 1999). "Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys". The American Journal of Psychiatry. 156 (12): 1915–1923. doi:10.1176/ajp.156.12.1915. ISSN0002-953X. PMID10588405. S2CID6527201.
Jiaxin Y, Xi F, Xiaoli L, Yamin L (2020). "Association of problematic smartphone use with poor sleep quality, depression, and anxiety: A systematic review and meta-analysis". Psychiatry Research. 284. Elsevier: 112686. doi:10.1016/j.psychres.2019.112686. PMID31757638. S2CID207974088.
Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, et al. (26 August 2014). "DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia-spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders". European Archives of Psychiatry and Clinical Neuroscience. 265 (2): 87–106. doi:10.1007/s00406-014-0521-9. PMID25155875. S2CID24165894.
Barić H, Đorđević V, Cerovečki I, Trkulja V (2018-03-01). "Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials". Advances in Therapy. 35 (3): 261–288. doi:10.1007/s12325-018-0680-6. ISSN1865-8652. PMID29508154. S2CID3939726.
Parsons TD, Rizzo AA (September 2008). "Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis". Journal of Behavior Therapy and Experimental Psychiatry. 39 (3): 250–261. doi:10.1016/j.jbtep.2007.07.007. PMID17720136. S2CID6688068.
Behar E, DiMarco ID, Hekler EB, Mohlman J, Staples AM (December 2009). "Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications". Journal of Anxiety Disorders. 23 (8): 1011–1023. doi:10.1016/j.janxdis.2009.07.006. ISSN1873-7897. PMID19700258. S2CID10962212.
Hidalgo RB, Tupler LA, Davidson JR (November 2007). "An effect-size analysis of pharmacologic treatments for generalized anxiety disorder". Journal of Psychopharmacology. 21 (8): 864–872. doi:10.1177/0269881107076996. ISSN0269-8811. PMID17984162. S2CID27127585.
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P (January 2017). "Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis%2FYIC.0000000000000147". International Clinical Psychopharmacology. 32 (1): 49–55. doi:10.1097/YIC.0000000000000147. ISSN0268-1315. PMID27643884. S2CID29623356.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (October 2012). "An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder". The World Journal of Biological Psychiatry. 13 (7): 510–516. doi:10.3109/15622975.2011.624548. ISSN1814-1412. PMID22059936. S2CID35359537.
Bandelow B, Wedekind D, Leon T (2007). "Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention". Expert Review of Neurotherapeutics. 7 (7): 769–81. doi:10.1586/14737175.7.7.769. PMID17610384. S2CID6229344.
Wensel TM, Powe KW, Cates ME (2012). "Pregabalin for the Treatment of Generalized Anxiety Disorder". Annals of Pharmacotherapy. 46 (3): 424–9. doi:10.1345/aph.1Q405. PMID22395254. S2CID26320851.
Perna G, Alciati A, Riva A, Micieli W, Caldirola D (March 2016). "Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review". Current Psychiatry Reports. 18 (3): 23. doi:10.1007/s11920-016-0668-3. ISSN1535-1645. PMID26830881. S2CID24141971.
Hettema JM, Neale MC, Kendler KS (October 2001). "A review and meta-analysis of the genetic epidemiology of anxiety disorders". The American Journal of Psychiatry. 158 (10): 1568–1578. doi:10.1176/appi.ajp.158.10.1568. ISSN0002-953X. PMID11578982.
Kessler RC, DuPont RL, Berglund P, Wittchen HU (December 1999). "Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys". The American Journal of Psychiatry. 156 (12): 1915–1923. doi:10.1176/ajp.156.12.1915. ISSN0002-953X. PMID10588405. S2CID6527201.
Barić H, Đorđević V, Cerovečki I, Trkulja V (2018-03-01). "Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials". Advances in Therapy. 35 (3): 261–288. doi:10.1007/s12325-018-0680-6. ISSN1865-8652. PMID29508154. S2CID3939726.
Bui E, Charney, Meredith E, Baker, Amanda W (2020). Clinical handbook of anxiety disorders: from theory to practice. Cham: Humana Press. ISBN978-3-030-30687-8. OCLC1134852696.
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P (January 2017). "Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis%2FYIC.0000000000000147". International Clinical Psychopharmacology. 32 (1): 49–55. doi:10.1097/YIC.0000000000000147. ISSN0268-1315. PMID27643884. S2CID29623356.
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (October 2012). "An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder". The World Journal of Biological Psychiatry. 13 (7): 510–516. doi:10.3109/15622975.2011.624548. ISSN1814-1412. PMID22059936. S2CID35359537.